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Abstract 
Defects in the biosynthesis of the oligosaccharide precursor for N-glycosylation lead to 
decreased occupancy of glycosylation sites and thereby to diseases known as Congenital 
Disorders of Glycosylation (CDG). In the last 20 years, approximately 1000 CDG patients 
have been identified presenting with multiple organ dysfunctions. This review sets the state of 
the art by listing all mutations identified in the 15 genes (PMM2, MPI, DPAGT1, ALG1, 
ALG2, ALG3, ALG9, ALG12, ALG6, ALG8, DOLK, DPM1, DPM3, MPDU1 and RFT1) 
yielding a deficiency of dolichol-linked oligosaccharide biosynthesis. The present analysis 
shows that most mutations lead to substitutions of strongly conserved amino acid residues 
across eukaryotes. Furthermore, the comparison between the different forms of CDG affecting 
dolichol-linked oligosaccharide biosynthesis shows that the severity of the disease does not 
relate to the position of the mutated gene along this biosynthetic pathway. 
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Introduction 
N-glycosylation is an essential form of post-translational modification in eukaryotes. Several 
types of N-glycosylation disorders have been described over the last decade, thereby 
expanding the list of congenital disorders of glycosylation (CDG) (Freeze, 2006). Looking at 
the N-glycosylation disorders identified so far, it is reasonable to predict that all genes 
involved in the biosynthesis of N-glycans are likely to be once associated with a form of 
CDG. Despite the achievement of the last years, the identification of novel N-glycosylation 
disorders remains challenging, mainly because of their rarity and because of their rather 
nonspecific clinical pictures (Leroy, 2006). The widespread application of a simple isoelectric 
focusing (IEF) test allowing the detection of underglycosylated serum transferrin (van Eijk, et 
al., 1983) has been instrumental in pointing at potential cases of N-glycosylation disorders. 
The pattern of transferrin glycoforms obtained by IEF usually allows differentiating between 
defects of N-glycosylation site occupancy and defects of N-glycan trimming and elongation. 
These two groups of defects have been originally defined as CDG type-I or CDG-I, and CDG 
type-II or CDG-II, respectively (Aebi, et al., 1999). Defects in other classes of glycosylation 
and in sugar-nucleotide transporters have also been designated as CDG-II (Lubke, et al., 
2001; Topaz, et al., 2004; Martinez-Duncker, et al., 2005). However, the recent description of 
glycosylation disorders caused by defects of vesicular transport (Wu, et al., 2004; Foulquier, 
et al., 2006; Foulquier, et al., 2007), which by definition fall in the category of CDG-II, has 
prompted for a revision of the CDG nomenclature. Along this line, it has been suggested to 
abandon the differentiation between CDG-I and -II, and to name the glycosylation disorders 
by using the official abbreviation of the defective gene (Jaeken, et al., 2008).  
Since the first description of mutations in the phosphomannomutase-2 (PMM2) gene as 
causing CDG (Matthijs, et al., 1997), 25 additional disorders of N-glycosylation have been 
identified (Jaeken, et al., 2008). Clinically, most of these disorders lead to psychomotor 
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retardation with variable neuromuscular involvement and additional features like hormonal 
abnormalities and coagulopathies (Leroy, 2006). The severity of these symptoms often varies 
tremendously, ranging from slight mental retardation to multiorgan dysfunctions often 
associated to infantile lethality. A typical question arising when comparing the clinical 
manifestations described is the following: does the severity of a CDG case relate to the 
position of the defect along the N-glycosylation biosynthetic pathway or rather to the degree 
of inactivation conferred by the mutation underlying the gene defect? This question can be 
particularly well examined when considering the glycosylation disorders caused by defective 
assembly of the dolichol-linked oligosaccharides since this biosynthetic pathway is sequential 
(Figure 1). Moreover, the assembly of  dolichol-linked oligosaccharides is strongly conserved 
among eukaryotes, thereby enabling the application of asparagine-linked glycosylation (ALG) 
mutant strains of the yeast Saccharomyces cerevisiae as tools for investigating the functional 
impact of human mutations (Westphal, et al., 2001a; Grubenmann, et al., 2004; Haeuptle, et 
al., 2008).  
The aim of this review is to define the state of the art for the known disorders of dolichol-
linked oligosaccharide biosynthesis and especially to discuss the effect of identified mutations 
on the functions of the affected proteins. To date, 15 gene defects have been described in this 
group (Matthijs, et al., 1997; Niehues, et al., 1998; Imbach, et al., 1999; Körner, et al., 1999; 
Imbach, et al., 2000b; Schenk, et al., 2001; Chantret, et al., 2002; Chantret, et al., 2003; Thiel, 
et al., 2003; Wu, et al., 2003; Frank, et al., 2004; Grubenmann, et al., 2004; Kranz, et al., 
2007b; Haeuptle, et al., 2008; Lefeber, et al., 2009). Common for all of these defects is the 
insufficient supply of dolichol-linked oligosaccharide precursor, which leads to decreased 
occupancy of N-glycosylation sites. The defective glycosylation reactions can be organized in 
five categories based on enzymatic activity and on subcellular localization (Fig. 1). The first 
category comprises the cytosolic enzymes PMM2 and mannose phosphate isomerase (MPI) 
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(Matthijs, et al., 1997; Niehues, et al., 1998). The second category includes the N-
acetylglucosaminyl- and mannosyltransferase enzymes involved in the assembly of the 
dolichol-linked oligosaccharide at the cytosolic side of the endoplasmic reticulum (ER) 
membrane (Thiel, et al., 2003; Wu, et al., 2003; Grubenmann, et al., 2004). The third and 
forth categories include the mannosyltransferase and glucosyltransferase enzymes that 
elongate the luminally-oriented dolichol-linked oligosaccharide (Imbach, et al., 1999; Körner, 
et al., 1999; Chantret, et al., 2002; Chantret, et al., 2003; Frank, et al., 2004), respectively, 
whereas the last category comprises the proteins that modify dolichol or affect the availability 
of dolichol-linked carbohydrates to the assembly pathway (Imbach, et al., 2000b; Schenk, et 
al., 2001; Kranz, et al., 2007b; Haeuptle, et al., 2008; Lefeber, et al., 2009).  
Over the last decade, close to 1000 CDG patients were diagnosed with a disorder of dolichol-
linked oligosaccharide assembly, thereby unravelling more than 200 mutations in 15 genes 
(Table 1). The present review provides a comprehensive overview of the pathway by mapping 
these mutations on model representations of the affected proteins. By integrating the clinical 
features associated with each mutation, this overview enables a discussion of the importance 
of individual proteins in the context of N-glycosylation output and human physiology. 
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Group 1: Cytosolic enzymes  
The glycosyltransferase enzymes of the N-glycosylation pathway use nucleotide- or dolichol-
activated monosaccharides as donor substrates. Defects in the biosynthesis of these substrates 
lead to CDG. The formation of GDP-Man occupies a central stage in the process considering 
the nine Man residues constituting the N-glycan core (Fig. 1). Accordingly, the cytosolic 
enzymes PMM2 and MPI, which catalyze the conversion of Man-6-P to Man-1-P and of 
fructose-6-P to Man-6-P, respectively, are essential members of the N-glycosylation pathway. 
Note worthily, PMM2 and MPI deficiencies affect additional glycosylation pathways, such as 
O-mannosylation and glycosylphosphatidylinositol-anchor biosynthesis, which also rely on 
Man-based donor substrates. 
 
PMM2 (PMM2-CDG, CDG-Ia) 
More than 800 patients have been identified with mutations in the PMM2 gene (PMM2-
CDG), thereby constituting the largest group of CDG cases (Table 1). Clinically, neurologic 
symptoms including psychomotor retardation, developmental delay, epilepsy, ataxia, 
cerebellar hypoplasia and visual impairment are predominant. Furthermore, symptoms of 
coagulopathy, hypotonia, cardiomyopathy, gastrointestinal and hepatic problems are also 
frequently observed. Strong dysmorphic features including severe skeletal deformities are 
found in most cases (Mizugishi, et al., 1999; Westphal, et al., 2001a; Briones, et al., 2002; 
Tayebi, et al., 2002; Ono, et al., 2003; Coman, et al., 2005; Schollen, et al., 2007; Vermeer, et 
al., 2007; Wurm, et al., 2007; Truin, et al., 2008; Perez-Duenas, et al., 2009; Thong, et al., 
2009; Vega, et al., 2009). A mortality rate of over 20% within the first years of life is frequent 
in cases presenting with low residual PMM2 activity (Matthijs, et al., 2000). The essential 
role of PMM2 is supported by finding that disruption of this gene in mice leads to early 
embryonic lethality (Thiel, et al., 2006). 
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PMM2-CDG is the most frequent form of CDG in respect to the number of mutations 
identified to date, which sums up to 103 (Supp. Table S1) (Matthijs, et al., 1997; Matthijs, et 
al., 1999; Mizugishi, et al., 1999; Matthijs, et al., 2000; Grunewald, et al., 2001; Westphal, et 
al., 2001a; Briones, et al., 2002; Schollen, et al., 2002; Tayebi, et al., 2002; Callewaert, et al., 
2003; Ono, et al., 2003; Coman, et al., 2005; Le Bizec, et al., 2005; Vuillaumier-Barrot, et al., 
2006; Schollen, et al., 2007; Vermeer, et al., 2007; Wurm, et al., 2007; Truin, et al., 2008; 
Perez-Duenas, et al., 2009; Thong, et al., 2009; Vega, et al., 2009). Three of them (p.Q37H, 
p.E197A and p.A233T) occur only in combination with two other heterozygous mutations and 
are therefore assumed to be single nucleotide polymorphisms. The mutations are scattered 
over the PMM2 gene and yield a broad range of protein defects (Fig. 2; Supp. Table S1). A 
total of 80 missense mutations affect 68 different amino acid residues. Five nonsense 
mutations introduce an early stop codon and lead to truncated PMM2 proteins. The seven base 
deletion and insertion mutations identified to date lead to frame shifts and thus to truncated 
proteins. A total of ten splicing defects have been described, whereas the causative mutations 
were not only found at the splicing sites, but also as far as 15 kb in intronic regions (Schollen, 
et al., 2007; Truin, et al., 2008; Vega, et al., 2009).  Finally, one patient displayed the 
complete loss of exon 8 due to a deletion mediated by an Alu retro-transposition (Schollen, et 
al., 2007). 
The human PMM2 enzyme is 246 amino acids long and shows a very high level of amino 
acid conservation among eukaryotes (Fig. 2).  The crystal structure of its isozyme PMM1 has 
been solved (Silvaggi, et al., 2006), which by extrapolation contributes to assign the impact of 
mutations on PMM2 protein function and stability. Interestingly, none of the amino acids 
constituting the active center have been found to be mutated in CDG. However, several 
mutations have been identified leading to declined substrate or cofactor binding. The 
arginines at position p.R150, p.R123 and p.R28 in PMM1 (equivalent to p.R141, p.R123 and 
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p.R21 in PMM2) were shown to be involved in binding either the phosphate or the C2 
hydroxyl group of the substrate (Silvaggi, et al., 2006). Substitution of these amino acids in 
PMM2 (Fig. 2) results in a severe clinical phenotype and it has been shown that 
homozygosity for the p.R141H mutation is not compatible with life (Matthijs, et al., 1998). 
The homodimeric interaction of PMM1 is mediated by a hydrophobic core, supported by 
surrounding hydrogen bonds and salt bridges (Silvaggi, et al., 2006). The mutations p.L104V, 
p.F119L, p.I120T in PMM2 might disrupt the analogous hydrophobic core (p.L113, p.F128 
and p.I129 in PMM1). Furthermore, the mutations p.E93A and p.N101K (p.E102 and p.N110 
in PMM1) are suspected to impair the homodimeric interaction by deletion of a hydrogen 
bond and a salt bridge (Fig. 2) (Silvaggi, et al., 2006). Other mutations have been shown to 
destabilize the overall protein fold and thereby leading to reduced catalytic activity (Pirard, et 
al., 1999).   
  
MPI (MPI-CDG, CDG-Ib) 
MPI-CDG can be detected biochemically by measuring MPI activity in patients’ fibroblasts or 
leukocytes (Jaeken, et al., 1998). In doing so, 25 patients have been identified so far, 
exhibiting 18 different mutations in the MPI gene (Jaeken, et al., 1998; Niehues, et al., 1998; 
Babovic-Vuksanovic, et al., 1999; de Lonlay, et al., 1999; Schollen, et al., 2000a; Westphal, 
et al., 2001b; Schollen, et al., 2002; Vuillaumier-Barrot, et al., 2002; Penel-Capelle, et al., 
2003; Vuillaumier-Barrot, 2005). The clinical presentation of these patients is unique due to 
the fact that neurological symptoms are usually absent. Mostly affected are the 
gastrointestinal tract and the liver with symptoms like diarrhoea, vomiting, gastrointestinal 
bleeding, protein-losing enteropathy, hepatomegaly and hepatic fibrosis. Additionally, 
coagulopathy, hypoglycaemia and thrombotic events have been observed in moderate to 
severe cases including at least six lethal outcomes (Jaeken, et al., 1998; Niehues, et al., 1998; 
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Babovic-Vuksanovic, et al., 1999; de Lonlay, et al., 1999; Westphal, et al., 2001b; 
Vuillaumier-Barrot, et al., 2002; Penel-Capelle, et al., 2003). Interestingly, MPI-CDG can 
effectively be treated by Man supplementation (Niehues, et al., 1998; Babovic-Vuksanovic, et 
al., 1999; de Lonlay, et al., 1999; Westphal, et al., 2001b; Penel-Capelle, et al., 2003). The 
orally applied Man could be phosphorylated by hexokinases yielding Man-6-P, and thereby 
enabling the functional bypass of the defective isomerase step (Panneerselvam and Freeze, 
1996).  
The human MPI enzyme is a soluble cytosolic protein of 423 amino acids (Fig. 3). The crystal 
structure of Candida albicans MPI (Cleasby, et al., 1996) suggests that the protein is a 
metallo-enzyme containing one zinc atom. Whereas most MPI domains show a rather low 
conservation status among eukaryotes, the central domain, forming the catalytic cleft, is 
highly conserved (Cleasby, et al., 1996). The human MPI shares 42% sequence homology 
with its C. albicans ortholog and is therefore assumed to present a similar protein fold.  
The 18 known mutations (Supp. Table S2) comprise a group of 15 point mutations, while 
only two frame-shift causing mutations and one splicing defect have been reported. Seven of 
these missense mutations map to the predicted catalytic domain, which ranges from cysteine 
p.C11 to phenylalanine p.F151 and from leucine p.L257 to arginine p.R322 based on the C. 
albicans MPI crystal structure (Cleasby, et al., 1996) (Fig. 3). The mutations of strictly 
conserved residues, such as p.M51T, p.S102L, p.M138T and p.I140T, lie in closest proximity 
to the active site and might directly impede the enzymatic activity. The p.R295H mutation 
converts a strictly conserved arginine, which corresponds to p.R304 in the C. albicans 
enzyme. This positively charged residue is positioned at the border of the active site cleft and 
is proposed to be responsible for substrate phosphate binding (Cleasby, et al., 1996). The 
remaining missense mutations alter amino acids of various degrees of conservation, thereby 
leading most probably to a destabilization of the MPI protein fold (Fig. 3).  
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Group 2: Cytosolically acting glycosyltransferases 
The assembly of the dolichol-linked oligosaccharide required for N-glycosylation is initiated 
on the cytosolic side of the ER membrane and proceeds up to the formation of the 
intermediate dolichol-PP-GlcNAc2Man5 (Fig. 1). Mutations in genes encoding three involved 
glycosyltransferases, namely DPAGT1, ALG1 and ALG2, have been found to cause CDG.  
 
DPAGT1 (DPAGT1-CDG, CDG-Ij) 
Deficiency of the UDP-GlcNAc:dolichol-phosphate GlcNAc-1-P transferase initiating the 
biosynthetic pathway leads to DPAGT1-CDG (Wu, et al., 2003). With only three patients and 
three mutations identified, it represents a rare form of CDG (Wu, et al., 2003; Vuillaumier-
Barrot, 2005). The clinical manifestations associated to DPAGT1 deficiency are unclear since 
only one of the three patients has been described clinically. This case presented with a 
developmental delay, microcephaly and exotropia, mental retardation, severe hypotonia and 
intractable seizures (Wu, et al., 2003). Unfortunately, the clinical description of the two other 
DPAGT1-CDG patients, a pair of siblings, is not available (Vuillaumier-Barrot, 2005). 
The human DPAGT1 is a hydrophobic protein of 408 amino acids that is predicted to span the 
ER membrane ten times (Fig. 4). The five loops assumed to protrude to the cytosol are mostly 
conserved among eukaryotes, which supports their function as part of the active center. One 
of the two identified missense mutations alters a highly conserved isoleucine at position 
p.I297, which localizes to the last of the five cytosolic loops (Fig. 4; Supp. Table S3). The 
other point mutation (p.Y170C), which maps to the fifth transmembrane (TM) domain, was 
found in combination with a splicing defect originating from an unknown genetic reason (Wu, 
12	
	
et al., 2003).  The third identified mutation is another splicing defect, assigned to a mutation 
within the first intron (c.162-8G>A) (Vuillaumier-Barrot, 2005). 
 
Mannosyltransferase 1 (ALG1-CDG, CDG-Ik)  
The phenotype of ALG1-CDG is very severe, given that at least four of seven patients died in 
childhood. Common symptoms are dysmorphic features, microcephaly, intractable seizures, 
hypotonia, coagulopathy and visual impairment (de Koning, et al., 1998; Grubenmann, et al., 
2004; Kranz, et al., 2004; Schwarz, et al., 2004).  Individual patients present with nearly the 
complete set of CDG symptoms including immunoglobulin G deficiency (Kranz, et al., 2004) 
and recurrent non-immune hydrops fetalis (de Koning, et al., 1998). 
The human ALG1 gene encodes a β-1,4 mannosyltransferase, which catalyses the addition of 
the first Man to dolichol-PP-linked chitobiose. The 464 amino acid protein is predicted to 
have a type-I ER membrane topology with a large cytosolic C-terminal domain harbouring the 
active site (Fig. 5). To date, four ALG1 mutations have been described (Supp. Table S4) (de 
Koning, et al., 1998; Grubenmann, et al., 2004; Kranz, et al., 2004; Schwarz, et al., 2004). 
However, one of three heterozygous point mutations (p.D429E) mapped in a single CDG 
patient, most likely represents a single nucleotide polymorphism (Grubenmann, et al., 2004). 
The residual three point mutations are spread all over the cytosolic domain, where they 
mainly convert weakly conserved amino acids (Fig. 5).  
 
Mannosyltransferase 2 (ALG2-CDG, CDG-Ii) 
The rarest form of  CDG described to date is the ALG2 mannosyltransferase deficiency with a 
single patient identified (Thiel, et al., 2003). This patient is only mildly affected with 
developmental delay, seizures, poor vision, coagulopathy and delayed myelinization. 
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Accordingly, it is not possible to draw any conclusion on the severity of ALG2-CDG from the 
description of this single case.  
The α-1,3 mannosyltransferase ALG2 enzyme is 416 amino acid-long and is predicted to form 
a type-I TM protein (Fig. 6). Like the ALG1 mannosyltransferase, its active site is 
cytosolically oriented and uses GDP-Man as donor substrate. Two heterozygous mutations 
were identified in the ALG2 gene of the index patient (Supp. Table S5). The first induces a 
frame-shift through a single base deletion (c.1040delG). The effect of the second mutation is 
unclear, since the point mutation, c.393G>T, results in an amino acid exchange (p.K131N), 
but also seems to alter the stability of the ALG2 transcript (Thiel, et al., 2003). 
 
Group 3: Luminally acting mannosyltransferases  
In the ER lumen, three mannosyltransferases catalyze the stepwise addition of the last four 
Man units ending with the formation of dolichol-PP-GlcNAc2Man9. Those three enzymes are 
hydrophobic proteins with multiple TM domains and use dolichol-P-Man as donor substrate. 
All of them have been related to a form of CDG.  
 
Mannosyltransferase 6 (ALG3-CDG, CDG-Id) 
The clinical presentation was comparable in most of the eleven ALG3-CDG patients and 
could be summarized as moderate with mainly neurological symptoms. Accordingly, the 
patients present with a failure to thrive, psychomotor retardation, epilepsy and microcephaly. 
Facial dysmorphism, hypotonia and visual impairment are also observed in the majority of the 
cases (Stibler, et al., 1995; Denecke, et al., 2005; Schollen, et al., 2005; Sun, et al., 2005a; 
Kranz, et al., 2007c; Rimella-Le-Huu, et al., 2008). However, a particular feature of this form 
of CDG constitutes deformations of hands and feet (Denecke, et al., 2005; Schollen, et al., 
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2005; Sun, et al., 2005a; Kranz, et al., 2007c; Rimella-Le-Huu, et al., 2008), which are not 
commonly seen in CDG.  
After being flipped into the ER lumen, the dolichol-PP-GlcNAc2Man5 intermediate is 
elongated for one Man unit by the ALG3 encoded α-1,3 mannosyltransferase 6. It is predicted 
to span the ER membrane seven times within its 438 amino acid sequence (Fig. 7). The 
asparagines at positions p.N83 and p.N253 represent potential N-glycosylation sites. The TM 
domains and the loops protruding to the ER lumen display the highest level of conservation 
among eukaryotes.  
The eleven ALG3-CDG cases account for eight point mutations and a single splicing defect 
(Supp. Table S6) (Stibler, et al., 1995; Körner, et al., 1999; Schollen, et al., 2002; Denecke, et 
al., 2004; Denecke, et al., 2005; Schollen, et al., 2005; Sun, et al., 2005a; Kranz, et al., 2007c; 
Rimella-Le-Huu, et al., 2008). Five of these missense mutations lead to substitutions of highly 
conserved amino residues within the luminally oriented loops (Fig. 7). Considering their 
degree of conservation and their orientation with respect to the ER membrane, these mutated 
amino acids are likely to be involved in the formation of the active center.  
 
Mannosyltransferase 7-9 (ALG9-CDG, CDG-Il) 
Only three cases of ALG9-CDG have been characterized to date (Frank, et al., 2004; 
Weinstein, et al., 2005; Vleugels, et al., 2009b). The corresponding patients presented with 
typical CDG symptoms such as developmental delay, psychomotor retardation, hypotonia, 
seizures, hepatomegaly, microcephaly and pericardial effusion. Gastrointestinal problems 
(Vleugels, et al., 2009b) and bronchial asthma (Frank, et al., 2004) were reported in one case. 
This form of CDG exhibits no unique feature and can be classified as moderate, although the 
three cases described to date do not allow drawing a conclusion on the clinical picture.  
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The two identified mutations (Supp. Table S7) occur homozygously in the ALG9 gene, which 
codes for a 611 amino acid α-1,2 mannosyltransferase. The enzyme, which is predicted to 
include eight TM domains and two N-glycosylation sites, catalyzes the addition of the seventh 
and the ninth Man of the dolichol-linked oligosaccharide. The mutations p.Y287C and 
p.E523K lie within conserved loops protruding into the ER lumen (Fig. 8) (Frank, et al., 2004; 
Weinstein, et al., 2005; Vleugels, et al., 2009b).  
 
Mannosyltransferase 8 (ALG12-CDG, CDG-Ig) 
Six of the eight characterized ALG12-CDG patients present a similar set of clinical features, 
including facial dysmorphism, psychomotor retardation, developmental delay, hypotonia and 
decreased coagulation factors. Prominent also are respiratory impairment, feeding problems 
and the absence of seizures, gastrointestinal and hepatic symptoms (Chantret, et al., 2002; 
Grubenmann, et al., 2002; Thiel, et al., 2002; Di Rocco, et al., 2005; Eklund, et al., 2005a). 
The low levels of serum immunoglobulin G define a possible indicator for 
mannosyltransferase 8 deficiency. The overall moderate severity of ALG12-CDG was also 
supported by the observation that some patients were actually able to walk and showed speech 
involvement (Eklund, et al., 2005a). However, two ALG12-CDG siblings demonstrate a much 
more severe disease (Kranz, et al., 2007a). In addition to the symptoms previously mentioned, 
these two patients presented with skeletal dysplasia, generalized oedema and audiovisual 
impairment. Both patients died within the first two years of life.  
The α-1,6 mannosyltransferase 8, encoded by the human ALG12 gene, transfers the eighth 
Man from dolichol-P-Man to the dolichol-linked oligosaccharide. The 488 amino acid protein 
is predicted to include eleven TM domains (Fig. 9). The enzyme is conserved among 
eukaryotes, whereas TM domains and the predicted loops oriented to the ER display the 
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highest level of conservation. Two asparagines at positions p.N250 and p.N463 represent 
consensus sequences for N-glycosylation.  
To date, eight ALG12-CDG cases have been described encompassing eleven mutations, 
whereof nine are missense, one nonsense and a single base deletion causing a frame shift 
(Supp. Table S8) (Chantret, et al., 2002; Grubenmann, et al., 2002; Thiel, et al., 2002; Di 
Rocco, et al., 2005; Eklund, et al., 2005a; Kranz, et al., 2007a). Noteworthy, nearly all 
mutations are mapped to TM domains or to their borders and most of these mutations lead to 
substitution of highly conserved amino acids (Fig. 9). The siblings, which presented with the 
more severe clinical features, were compound heterozygous for the p.G101R and the p.R146Q 
mutations (Kranz, et al., 2007a). While the first mutation is so far unique, the second was 
already discovered in another case of ALG12-CDG in combination with the p.T67M mutation 
(Grubenmann, et al., 2002). According to the severe clinical outcome, the p.G101 and the 
p.R146 residues seem to be essential for ALG12 functionality. This assumption is supported 
by finding that the glycine at position p.G101 is highly conserved among eukaryotes, while 
the arginine at position p.R146 is even strictly conserved in all eukaryotic model organisms 
examined (Fig. 9).  
 
Group 4: Luminally acting glucosyltransferases  
The biosynthesis of the dolichol-linked oligosaccharide is completed by the successive 
addition of three Glc units (Fig. 1). This task is achieved by three ER membrane 
glucosyltransferases, encoded by the ALG6, the ALG8 and the ALG10 gene, which utilize 
dolichol-P-Glc as donor substrate. While defects in the first two enzymes have been 
associated to CDG, no mutation in the ALG10 gene has so far been identified.  
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Glucosyltransferase 1 (ALG6-CDG, CDG-Ic): 
The deficiency of ALG6 glucosyltransferase is the second most frequent form of CDG after 
PMM2-CDG with 36 cases registered so far and representing 20 distinct mutations (Imbach, 
et al., 1999; Grunewald, et al., 2000; Hanefeld, et al., 2000; Imbach, et al., 2000a; Westphal, 
et al., 2000a; Westphal, et al., 2000b; de Lonlay, et al., 2001; Schollen, et al., 2002; Newell, et 
al., 2003; Westphal, et al., 2003; Sun, et al., 2005b; Vuillaumier-Barrot, 2005; Eklund, et al., 
2006). The clinical presentation could be described as mild to moderately severe with 
psychomotor retardation, developmental delay, seizures, hypotonia, coagulopathy, feeding 
problems and visual impairment. The occurrence of strong dysmorphic features, 
gastrointestinal problems or protein-losing enteropathy is rather rare. 
The ALG6 α-1,3 glucosyltransferase is 507 amino acid-long and is predicted to span the ER 
membrane eleven times (Fig. 10). The 20 ALG6 mutations represent nine missense, one 
nonsense, four splicing and five deletion mutations (Supp. Table S9). In one case, a portion of 
the chromosome 1 including the ALG6 gene is deleted as a de novo event (Eklund, et al., 
2006). Two of the identified point mutations (p.Y131H and p.F304S) are assumed to be single 
nucleotide polymorphisms (Vuillaumier-Barrot, et al., 2001; Westphal, et al., 2003). While 
these single nucleotide polymorphisms do not appear to be pathogenic by themselves, they 
may lead to reduced N-glycosylation when combined to other mutations along the pathway of 
dolichol-linked oligosaccharide assembly (Westphal, et al., 2002). Surprisingly, three of the 
five deletion mutations lead to an in-frame removal of isoleucine at position p.I299 (Hanefeld, 
et al., 2000; Westphal, et al., 2000b; Sun, et al., 2005b). The deletion of three consecutive 
base triplets in three independent patients determines a deletion hotspot. The amino acids 
surrounding p.I299 are encoded to some extend by the DNA repeat c.382TAATAAT, which 
might facilitate deletions. The majority of the mutations affect amino acids positioned within 
the eleven TM domains (Fig. 10). This fact suggests that TM domains might not only play an 
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important role in defining the protein structure, but also in catalysis, presumably through the 
binding to dolichol-linked substrates. Two missense mutations (p.R113H and p.S170I) change 
strictly conserved amino residues mapping to ER luminal loops, which might constitute part 
of the active site (Fig. 10).  
 
Glucosyltransferase 2 (ALG8-CDG, CDG-Ih) 
Whereas ALG6 deficiency yields a rather mild form of CDG, mutations in the ALG8 
glucosyltransferase gene lead to a severe form of the disease. Five of nine ALG8 deficient 
patients died within the first months of life (Schollen, et al., 2004; Eklund, et al., 2005b; 
Stölting, et al., 2009; Vesela, et al., 2009). These cases were accompanied by multiple 
symptoms like strong dysmorphic features, hypotonia, gastrointestinal disorders, 
hepatomegaly, coagulopathy, oedema, cardio-respiratory problems, protein-losing 
enteropathy and ascites. Remarkably, neurologic involvement was either minimal in most of 
the patients (Chantret, et al., 2003; Schollen, et al., 2004; Eklund, et al., 2005b; Vesela, et al., 
2009). However, a pair of siblings displayed a much milder form of ALG8 deficiency. 
Besides dysmorphic features, they presented with hypotonia, ataxia, mental retardation 
(Stölting, et al., 2009).    
The ALG8 α-1,3 glucosyltransferase is predicted to be an eleven TM domain ER protein with 
a size of 526 amino acids (Fig. 11). To date, twelve mutations have been described (Supp. 
Table S10) (Chantret, et al., 2003; Schollen, et al., 2004; Eklund, et al., 2005b; Stölting, et al., 
2009; Vesela, et al., 2009). The p.N222S mutation is likely to represent a single nucleotide 
polymorphism, since the healthy father of a patient is homozygous for this mutation 
(Schollen, et al., 2004). The other eleven mutations segregate into four missense mutations, 
one nonsense mutation, three splicing defects and three frame-shift mutations. The missense 
mutations p.T47P, p.P69L, p.G275D and p.A282V locate to ER luminal domains and lead to 
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substitutions of strictly conserved amino (Fig. 11), thereby probably disrupting the enzymatic 
center. The residual mutations, leading to truncated forms of the ALG8 protein, decrease the 
catalytic ability of the affected enzyme drastically. This might, at least partly, explain the 
severe progression of ALG8-CDG. 
 
Group 5: Proteins affecting dolichol-linked carbohydrates  
In addition to the cytosolic PMM2 and PMI enzymes and the ER glycosyltransferases, a 
handful of proteins are also involved in the biosynthesis of the dolichol-linked 
oligosaccharide required for N-glycosylation. Some of these proteins have an established 
activity, whereas others represent essential components without clearly assigned functions. By 
phosphorylating dolichol, the dolichol kinase enzyme enables the transfer of GlcNAc-P to 
dolichol-P, thereby initiating the biosynthesis of dolichol-linked oligosaccharide (Fig. 1) 
(Shridas and Waechter, 2006). The products of the DPM genes form a trimeric complex that 
catalyses the synthesis of dolichol-P-Man (Maeda and Kinoshita, 2008). In contrast to the 
previous enzymes, the function of the MPDU1 and RFT1 proteins can only be predicted. 
MPDU1 and its hamster ortholog Lec35 have been proposed to be involved in the utilization 
of the sugar donor substrates dolichol-P-Man and -Glc (Anand, et al., 2001; Schenk, et al., 
2001). The RFT1 protein has been demonstrated to be involved in the translocation of the 
dolichol-linked GlcNAc2Man5 intermediate into the ER lumen (Helenius, et al., 2002). 
Although the proteins included in this group have diverse biological functions, they all yield 
to a CDG phenotype in case of mutation.  
 
Dolichol kinase (DOLK-CDG, CDG-Im) 
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Four cases of DOLK-CDG have been reported to date (Kranz, et al., 2007b). The loss of 
dolichol kinase affects the biosynthesis of dolichol-linked oligosaccharides, therefore it is also 
classified as a form of CDG. All four reported patients died in early childhood (Kranz, et al., 
2007b). This very severe clinical phenotype is marked by hypotonia, skin disorders and the 
loss of hair. Individual patients also presented with cardiomyopathy, seizures, hypoglycaemia, 
microcephaly and visual impairment (Kranz, et al., 2007b). 
The mainly hydrophobic 538 amino acids of the dolichol kinase are predicted to form a 15 
TM domain protein, which might be glycosylated at asparagine p.N500 (Fig. 12). This 
prediction differs slightly with an earlier model, which assigned 13 membrane spanning 
domains (Shridas and Waechter, 2006). Nevertheless, the N- and the C-termini, as well as the 
strongly conserved putative CTP-binding pocket (p.S459–p.E474) respect the experimentally 
proven  orientation of the human enzyme regarding the ER membrane (Fig. 12) (Shridas and 
Waechter, 2006). The level of sequence conservation of the N-terminal region is relatively 
low, because the Caenorhabditis elegans dolichol kinase, with its 281 amino acids, is much 
shorter than the average dolichol kinases’ size in other organisms. This short enzyme overlaps 
mainly within the C-terminal part, containing the putative CTP-binding domain (Fig. 12). One 
of the two homozygously occurring point mutations converts a mainly conserved tyrosine 
(p.Y441S) in the C-terminal part of the kinase (Supp. Table S11). The other mutation leads to 
the alteration of a non-conserved cysteine at position p.C99 to a serine, this time in the N-
terminal part of the enzyme (Fig. 12). The severe outcome of two trivial point mutations 
indicates that accurate dolichol kinase function is essential for viability. This statement might 
not only be due to a defect of N-glycosylation since other functions are assigned to dolichol 
and dolichol-P (Swiezewska and Danikiewicz, 2005). 
 
Dolichol-P-Man synthase (DPM1-CDG, CDG-Ie and DPM3-CDG, CDG-Io) 
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Recurrent seizures, hypotonia, developmental delay, dysmorphic features, microcephaly, 
visual impairment and in some cases ataxia and coagulopathy are the most prominent 
symptoms found in DPM1-CDG patients (Imbach, et al., 2000b; Kim, et al., 2000; Garcia-
Silva, et al., 2004; Dancourt, et al., 2006). The individual cases exhibit certain clinical 
variations, although all in the range of moderate to severe. The index DPM3-CDG patient 
described recently (Lefeber, et al., 2009) presented with a very mild phenotype. Except for a 
mild myopathy, a dilated cardiomyopathy, moderate muscular dystrophy and a single stroke 
like episode the adult patient is able to lead a virtually normal life.  
In humans, dolichol-P-Man synthase is an oligomeric enzyme complex assembled by the 
DPM1, DPM2 and DPM3 gene products. So far, the 260 amino acid-long catalytic subunit 
DPM1 and the tethering polypeptide DPM3 have been described as causes of CDG. DPM2 
and DPM3, both ER membrane proteins with each two TM domains and a length of 84 and 92 
amino acids, respectively, are required to target the cytosolic DPM1 protein to the ER 
membrane. While DPM3 interacts directly with DPM1, DPM2 stabilizes the complex by 
binding to DPM3 (Fig. 13) (Maeda and Kinoshita, 2008).  
To date, eight DPM1-CDG patients have been described, which represented six distinct 
mutations (Supp. Table S12) (Imbach, et al., 2000b; Kim, et al., 2000; Garcia-Silva, et al., 
2004; Vuillaumier-Barrot, 2005; Dancourt, et al., 2006). Three of the mutations are deletions 
or splice defects and lead all to a frame-shift and hence to truncated forms of the enzyme. The 
three point mutations convert single amino acids of various conservation levels at different 
sites of the DPM1 protein (Fig. 13). In DPM3, the homozygous point mutation p.L85S 
converts a strictly conserved leucine residue within the terminal coiled-coil domain, which is 
required for tethering the catalytic DPM1 subunit to the ER membrane (Supp. Table S13) 
(Lefeber, et al., 2009). Notably, mutations in the DPM complex lead not only to a disorder of 
N-glycosylation, but also O-mannosylation and glycosylphosphatidylinositol-anchor 
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formation are impaired, since dolichol-P-Man is utilized as donor substrate for these 
posttranslational modifications as well (Maeda and Kinoshita, 2008). 
 
Man-P-dolichol utilizing defect 1 (MPDU1-CDG, CDG-If) 
The clinical outcome of the four described MPDU1-CDG patients is variable. While one 
patient died in early childhood due to a seizure induced apnea, the others present with mild to 
moderately severe phenotypes. Shared symptoms are psychomotor retardation, seizures, 
hypotonia, gastrointestinal problems, visual impairment and, as an atypical hallmark, skin 
disorders (Kranz, et al., 2001; Schenk, et al., 2001). 
The human MPDU1 gene, whose product is orthologous to the Chinese hamster Lec35 
protein, encodes a 247 amino acid ER membrane protein that is predicted to form six TM 
domains (Fig. 14). Despite its important role in mammalian N-glycosylation, no Lec35 
ortholog could be identified in the yeast S. cerevisiae. The Man-P-dolichol utilizing defect 1 
protein has been proposed to be involved in the lateral distribution of dolichol-P-Man and 
dolichol-P-Glc within the ER membrane (Schenk, et al., 2001). It is therefore important for 
the availability of these sugar substrates to the ER mannosyl- and glucosyltransferases. 
Accordingly, MPDU1 deficiency leads to the accumulation of dolichol-PP-GlcNAc2Man5 and 
dolichol-PP-GlcNAc2Man9 intermediates (Kranz, et al., 2001; Schenk, et al., 2001). The four 
cases of MPDU1-CDG characterized to date revealed five mutations (Supp. Table S14). Four 
of them are common missense mutations and the fifth is the deletion of a single nucleotide 
(c.511delC), which leads to a frame-shift (Kranz, et al., 2001; Schenk, et al., 2001). The 
mutation of the start methionine in one of the patient’s allele switches the translation start to 
the next methionine in a different frame and thus leads to the loss of the MPDU1 protein 
(Schenk, et al., 2001).  The other point mutations affect highly conserved amino acids 
throughout the protein (Fig. 14). 
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RFT1 (RFT1-CDG, CDG-In) 
Mutations in the RFT1 gene have only been described recently. They lead to the accumulation 
of dolichol-PP-GlcNAc2Man5 (Haeuptle, et al., 2008; Vleugels, et al., 2009a). The exact 
function of the RFT1 protein is currently intensively discussed. It is definitely involved in the 
translocation of the dolichol-linked oligosaccharide GlcNAc2Man5 into the ER lumen, but it 
has still to be demonstrated whether RFT1 is the flippase itself (Helenius, et al., 2002; Frank, 
et al., 2008). At any rate, mutations in the RFT1 gene lead to a disorder of N-glycosylation 
termed RFT1-CDG (Haeuptle, et al., 2008). At least two of the six patients died in childhood, 
suggesting a severe phenotype. Common clinical features include developmental delay, 
hypotonia, seizures, feeding problems, dysmorphic features and sensorineural deafness, which 
could be taken as a characteristic feature. In addition, some patients suffered from 
coagulopathy, visual impairment and respiratory problems (Haeuptle, et al., 2008; Vleugels, 
et al., 2009a). 
The human RFT1 protein with its 541 amino acids spans the ER membrane eleven times 
according to prediction algorithms (Fig. 15). The asparagine at position p.N227 might be N-
glycosylated. All five identified point mutations convert strongly conserved amino acids 
(Supp. Table S15) (Haeuptle, et al., 2008; Vleugels, et al., 2009a). Interestingly, one patient is 
heterozygous for two different point mutations affecting the same nucleotide (c.887T>A/G) 
and consequently modifying the same amino acid differently (p.I296K/R).  All mutated 
residues are localized to the first three ER luminally-oriented loops of the RFT1 protein. 
These loops display, together with the TM domains, an overall high conservation among 
species and might therefore be important for RFT1 functionality (Fig. 15).
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Discussion 
The comparison of nearly 1000 cases of deficient dolichol-linked oligosaccharide 
biosynthesis (Table 1) conveys interesting facts regarding the clinical severity of the disease 
in relation to the position of the genetic defect along the biosynthetic pathway. The 
biosynthesis of dolichol-linked oligosaccharides is sequential (Kornfeld and Kornfeld, 1985) 
(Fig. 1), meaning that a block along the pathway will result in the accumulation of an 
incomplete oligosaccharide. The oligosaccharyltransferase (OST) complex transfers 
preferentially the complete oligosaccharide to asparagine residues on acceptor proteins, but 
incomplete oligosaccharides can to some extent be recognized by OST and transferred to 
proteins, yet to a low efficiency (Körner, et al., 1999; Cipollo, et al., 2001). It is expected that 
this efficiency decreases with the degree of incompleteness of the dolichol-linked 
oligosaccharide. Accordingly, deficiency of ALG3 and ALG9 should be more severe than 
deficiency of ALG6 and ALG8. Furthermore, deficiency of cytosolically active enzymes like 
ALG1 and ALG2 should be even more severe, because the accumulating dolichol-linked 
oligosaccharides remain unavailable to the luminally-oriented OST complex. This gradation 
in the level of N-glycosylation output based on the position of the genetic defect is clearly 
visible in yeast glycosylation mutants (Huffaker and Robbins, 1982; Kukuruzinska and 
Robbins, 1987; Jackson, et al., 1993; Stagljar, et al., 1994; Burda and Aebi, 1998). However, 
such a position effect is not clear-cut when examining human CDG cases. This model would 
predict that the terminal glucosylation defects seen in ALG6 and ALG8 deficiency would be 
milder than the mannosylation defects seen in ALG3, ALG9 and ALG12 deficiency, for 
example. However, the association of ALG8 deficiency with a very severe disease (Schollen, 
et al., 2004) indicates that even dolichol-linked oligosaccharides lacking the terminal two Glc 
residues accounts for a profound disorder of N-glycosylation. The severity of ALG8-CDG 
suggests that protein underglycosylation may not be the only defect underlying the disease. 
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Since the terminal Glc residues of N-glycans are involved in the quality control of 
glycoprotein folding (Ellgaard and Helenius, 2003), it is possible that glucosylated dolichol-
linked oligosaccharides participate to the regulation of this process, too, as for example 
through the regulation of glucosidase-II activity (Deprez, et al., 2005). Consequently, 
alteration of glycoprotein folding might also account for the severity of ALG8-CDG.  
The absence of ALG10 defects among CDG cases described to date is surprising. The ALG10 
enzyme catalyzes the addition of the third Glc (Burda and Aebi, 1998) of the dolichol-linked 
oligosaccharide (Fig. 1). Assuming that all defects of dolichol-linked oligosaccharide 
biosynthesis lead to a disorder of N-glycosylation, ALG10 defects would be expected to 
present with clinical features typical of CDG. Hence, it is puzzling that no case of ALG10 
deficiency has been documented yet. On the other hand, this absence of ALG10 deficiency 
may be explained if the defect indeed does not significantly impair the process of N-
glycosylation, thereby remaining clinically undetectable. At the other side of the scale, it 
could be that ALG10 is essential for embryonic development and that even a minor decrease 
of ALG10 activity may not be compatible with life. To further address this question, it is 
important to continue screening for new forms of CDG. 
The identification of additional mutations and gene defects, especially in the glycosylation 
genes that have not been associated to CDG yet (Fig. 1), will provide additional evidence on 
the relationship between the extent of N-glycosylation, the position along the biosynthetic 
pathway and the severity of the clinical picture. Interestingly, a similar absence of position 
effect is also observed in the forms of congenital muscular dystrophies that are caused by 
defects of O-mannosylation. In fact, the clinical severity of the disorders is related to the 
nature of the mutation rather than by the position of the mutated gene along the O-
mannosylation pathway (Godfrey, et al., 2007). 
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Clinical relevance 
The analysis of mutations identified to date shows that 150 of the total 203 genetic alterations 
(Table 1) are missense mutations, whereas 112, i.e. 75%, of these mutations affect highly 
conserved amino acid residues among eukaryotic proteins. Since conserved amino acids are 
usually parts of functional motifs (Kinch and Grishin, 2002), it can be assumed that most 
CDG mutations alter the functions of the affected proteins. Accordingly, mutations of little 
conserved amino acids would yield minor enzymatic deficiencies that may be accompanied 
by mild symptoms or even remain asymptomatic. Along this line, it can be predicted that 
proteins showing the highest degree of sequence conservation among eukaryotes are likely to 
be more often associated with a disease phenotype. In case of dolichol-linked oligosaccharide 
biosynthesis, the PMM2 protein is by far the most conserved protein of the pathway (Fig. 2). 
Supporting this fact, half of the known mutations (103 out of 203) affect the PMM2 gene 
(Table 1). However, other proteins of the pathway also show a high degree of sequence 
conservation among eukaryotes, as for example the MPI and DPAGT1 proteins (Fig. 3 and 4). 
Yet, only three mutations have been found in the DPAGT1 gene so far, indicating that 
sequence conservation alone does not account for the incidence of a genetic disease. 
By examining the occurrence of PMM2 mutations, Schollen et al. (Schollen, et al., 2000b) 
noticed that the p.R141H mutation is very prevalent in the European population with a carrier 
frequency of about 1/70. Since this mutation is never found at the homozygous state in CDG 
patients (Matthijs, et al., 1998) due to its inactivating properties on PMM2 activity, it can only 
be assumed that a selection pressure accounts for the maintenance of this mutation in human 
populations. However, the nature of this selection pressure is unknown and one can only 
speculate as to whether a reduction of N-glycosylation is related to reducing the susceptibility 
to pathogens binding N-glycans as receptors. Such arguments are beyond the scope of this 
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review, but they certainly provide exciting points of reflection when discussing the biological 
and evolutionary relevance of glycosylation disorders. 
Future Prospects 
The analysis of mutations in genes involved in dolichol-linked oligosaccharide biosynthesis 
shows that they mainly affect conserved amino acid residues, thereby impairing protein 
function.  Since a complete loss of protein function is usually not compatible with life, as seen 
in mice lacking PMM2, MPI and DPAGT1 activity (Marek, et al., 1999; DeRossi, et al., 
2006; Thiel, et al., 2006), the mutations encountered in CDG certainly enable a significant 
level of N-glycosylation output. At the threshold of normal N-glycosylation, the transferrin 
IEF test may be not sensitive enough to detect N-glycosylation defects caused by mild 
mutations. The study of these mutations may represent the next challenge in CDG research, 
since mild disorders of glycosylation are often associated to mild neurological presentations 
such as slight mental retardation (Giurgea, et al., 2005). The development of new sensitive 
tests will certainly contribute to determine the true incidence of CDG and to better understand 
the physiological impact of N-glycosylation. 
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Figure legends 
 
Figure 1. Pathway of dolichol-linked oligosaccharide biosynthesis. After phosphorylation 
(P) of the lipid carrier dolichol (red bar), two GlcNAc (blue box), nine Man (green circle) and 
three Glc (blue circle) units are successively added by various glycosyltransferases. 
Nucleotide activated monosaccharides serve as donor substrates for the cytosolically oriented 
enzymes. After being translocated into the endoplasmic reticulum (ER) lumen, the 
intermediate dolichol-PP-GlcNAc2Man5 is further extended by luminally acting mannosyl- 
and glucosyltransferases using dolichol-P activated Man and Glc as sugar building blocks. 
The complete structure dolichol-PP-GlcNAc2Man9Glc3 is transferred to selected asparagines 
on newly synthesized glycolproteins by the oligosaccharyltransferase (OST) complex. The 
gene symbols are indicated next to the catalyzed reactions. The 15 genes associated with CDG 
are marked in red. 
  
Figure 2. Schematic model of PMM2. PMM2 protein sequences were aligned using the 
ClustalW program (Thompson, et al., 1994). The Homo sapiens sequence (NP_000294.1) was 
compared to the rodent Mus musculus (NP_058577.1), to the zebra fish Danio rerio 
(NP_956378.1), to the fruit fly Drosophila melanogaster (NP_648589.1), to the nematode 
Caenorhabditis elegans (NP_502698.2) and to the budding yeast Saccharomyces cerevisiae 
(NP_116609.1). Sequences were obtained from the Genbank (http://www.ncbi.nlm.nih.gov/ 
Genbank/index.html). Black dots represent strictly conserved amino acids and dark gray, light 
gray, white, those amino acids with a conservation of 83%, 67% and less than 67%, 
respectively. Mis- and nonsense mutations are marked next to the affect amino acids. The 
dark red, light red, orange and yellow dots mark the mutated amino acids that are conserved at 
100%, 83%, 67% and less than 67%, respectively. Splicing defects are marked with a bar and 
explicitly entitled in the case of assigned exon skipping. Further or unknown implications on 
the protein level of the affected enzyme are termed with splicing.  Deletion or insertion 
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mutations causing a frame-shift are marked with a bar as well and entitled as frame-shift, 
whereas the position of the resulting premature stop codon is given in brackets.  
 
Figure 3. Schematic model of MPI. Mutations and the conservation of the MPI amino acids 
among the human (NP_002426.1), mouse (NP_080113.1), zebra fish (NP_001028282.1), fruit 
fly (NP_649940.1), nematode (NP_499174.3) and budding yeast (NP_010918.1) proteins 
were mapped as in Figure 2.  
 
Figure 4. Schematic model of DPAGT1. Mutations and the conservation of the DPAGT1 
amino acids among the human (NP_001373.2), mouse (NP_031901.2), zebra fish 
(NP_001082880.1), fruit fly (NP_609608.1), nematode (NP_507859.2) and budding yeast 
(NP_009802.1) proteins were mapped as in Figure 2. The membrane topology prediction of 
the DPAGT1 enzyme was performed running the TMpred 
(http://www.ch.embnet.org/software/TMPRED_form.html), the TMHMM 
(http://www.cbs.dtu.dk/services/TMHMM-2.0/) (Krogh, et al., 2001), the DAS 
(http://www.sbc.su.se/~miklos/DAS/) (Cserzo, et al., 1997) and the SOSUI 
(http://bp.nuap.nagoya-u.ac.jp/sosui/sosui_submit.html) (Hirokawa, et al., 1998) algorithms. 
 
Figure 5. Schematic model of mannosyltransferase 1 (ALG1). Mutations and the 
conservation of the ALG1 amino acids among the human (NP_061982.3), mouse 
(NP_663337.2), zebra fish (NP_956161.1), fruit fly (NP_650662.1), nematode (AAC77507.2) 
and budding yeast (NP_009668.1) proteins were mapped as in Figure 2. Membrane topology 
prediction of the mannosyltransferase 1 was performed like for the DPAGT1 enzyme (Fig. 4). 
 
Figure 6. Schematic model of mannosyltransferase 2 (ALG2). Mutations and the 
conservation of the ALG2 amino acids among the human (NP_149078.1), mouse 
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(NP_064382.3), zebra fish (NP_001098406.1), fruit fly (NP_647772.1), nematode 
(NP_495010.2) and budding yeast (NP_011450.1) proteins were mapped as in Figure 2. 
Membrane topology prediction of the mannosyltransferase 2 was performed like for the 
DPAGT1 enzyme (Fig. 4).  
 
Figure 7. Schematic model of mannosyltransferase 6 (ALG3). Mutations and the 
conservation of the ALG3 amino acids among the human (NP_005778.1), mouse 
(NP_666051.2), zebra fish (NP_001018532.1), fruit fly (NP_523829.2), nematode 
(NP_496950.2) and budding yeast (NP_009471.1) proteins were mapped as in Figure 2. 
Membrane topology prediction of the mannosyltransferase 6 was performed like for the 
DPAGT1 enzyme (Fig. 4). Two potential N-glycosylation sites at position p.N83 and p.N253 
are shown schematically. 
 
Figure 8. Schematic model of mannosyltransferase 7-9 (ALG9). Mutations and the 
conservation of the ALG9 amino acids among the human (NP_001071158.1), mouse 
(NP_598742.1), zebra fish (CAN88585.1), fruit fly (NP_651353.1), nematode (NP_496282.2) 
and budding yeast (NP_014180.1) proteins were mapped as in Figure 2. Membrane topology 
prediction of the mannosyltransferase 7-9 was performed like for the DPAGT1 enzyme (Fig. 
4). Two potential N-glycosylation sites at position p.N77 and p.N593 are shown 
schematically. 
 
Figure 9. Schematic model of mannosyltransferase 8 (ALG12). Mutations and the 
conservation of the ALG12 amino acids among the human (NP_077010.1), mouse 
(EDL04396.1), zebra fish (NP_001092219.1), fruit fly (NP_649939.1), nematode 
(NP_505071.1) and budding yeast (NP_014427.1) proteins were mapped as in Figure 2. 
Membrane topology prediction of the mannosyltransferase 8 was performed like for the 
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DPAGT1 enzyme (Fig. 4). Two potential N-glycosylation sites at position p.N250 and 
p.N463 are shown schematically.  
 
Figure 10. Schematic model of glucosyltransferase 1 (ALG6). Mutations and the 
conservation of the ALG6 amino acids among the human (NP_037471.2), mouse 
(NP_001074733.1), fruit fly (NP_609393.1), nematode (NP_495685.1) and budding yeast 
(NP_014644.1) proteins were mapped as in Figure 2. The protein sequence of Tetraodon 
nigroviridis (CAG11585.1) was used instead of the zebra fish protein, since only a truncated 
D. rerio isoform could be retrieved from the genome database. Membrane topology prediction 
of the glucosyltransferase 1 was performed like for the DPAGT1 enzyme (Fig. 4). A potential 
N-glycosylation site at position p.N59 is shown schematically.  
 
Figure 11. Schematic model of glucosyltransferase 2 (ALG8). Mutations and the 
conservation of the ALG8 amino acids among the human (NP_076984.2), mouse 
(NP_950200.2), zebra fish (NP_001017647.1), fruit fly (NP_572355.1), nematode 
(NP_001021940.1) and budding yeast (NP_014710.1) proteins were mapped as in Figure 2. 
Membrane topology prediction of the glucosyltransferase 2 was performed like for the 
DPAGT1 enzyme (Fig. 4). A potential N-glycosylation site at position p.N96 is shown 
schematically. 
 
Figure 12. Schematic model of dolichol kinase (DOLK). Mutations and the conservation of 
the DOLK amino acids among the human (NP_055723.1), mouse (NP_808316.1), zebra fish 
(NP_001103954.1), fruit fly (NP_611139.1), nematode (NP_001022925.1) and budding yeast 
(NP_013726.1) proteins were mapped as in Figure 2. The C. elegans dolichol kinase is much 
shorter than the other eukaryotic orthologs, leading to an overall reduced conservation grade 
within the N-terminal part. Membrane topology prediction of the dolichol kinase was 
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performed like for the DPAGT1 enzyme (Fig. 4). A potential N-glycosylation site at position 
p.N500 is shown schematically. 
 
Figure 13. Schematic model of dolichol-P-Man synthase (DPM1/2/3). Mutations and the 
conservation of the DPM1 amino acids among the human (NP_003850.1), mouse 
(NP_034202.1), zebra fish (NP_001003596.1), fruit fly (NP_609980.1), nematode 
(NP_499931.2) and budding yeast (NP_015509.1) proteins were mapped as in Figure 2. 
Conservation of the DPM2 amino acids among the human (NP_003854.1), mouse 
(NP_034203.1) and zebra fish (NP_001116318.1) proteins and of the DPM3 amino acids 
among the human (NP_714963.1), mouse (NP_081043.1), zebra fish (NP_957103.2), fruit fly 
(NP_001034051.1) and nematode (NP_502366.1) proteins and the DPM3 mutation were also 
mapped as in Figure 2. Given that the S. cerevisiae dolichol-P-Man synthase is a monomeric 
enzyme (Maeda and Kinoshita, 2008), the DPM2 (NP_595676.1) and DPM3 (NP_596640.1) 
protein sequences from Schizosaccharomyces pombe were used for the  particular alignments. 
Additionally, the aberrant DPM2 sequences of D. melanogaster and C. elegans were 
displaced by the DPM2 proteins of Drosophila ananassae (EDV40477.1) and Dictyostelium 
discoideum (XP_644349.1), respectively. Membrane topology prediction of the dolichol-P-
Man synthase subunits 2 and 3 was performed like for the DPAGT1 enzyme (Fig. 4). The 
organization of the entire complex was adapted from Maeda et al. (Maeda and Kinoshita, 
2008).  
 
Figure 14. Schematic model of Man-P-dolichol utilizing defect 1 (MPDU1). Mutations and 
the conservation of the MPDU1 amino acids among the human (NP_004861.2), mouse 
(NP_036030.2), zebra fish (NP_001002130.1), fruit fly (NP_608889.1) and nematode 
(NP_505155.1) proteins were mapped as in Figure 2. Since MPDU1 is neither present in S. 
cerevisiae nor in S. pombe, the orthologous protein of Aspergillus niger (XP_001401680.1) 
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was used for the alignment. Membrane topology prediction of the Man-P-dolichol utilizing 
defect 1 protein was performed like for the DPAGT1 enzyme (Fig. 4).  
 
Figure 15. Schematic model of RFT1. Mutations and the conservation of the RFT1 amino 
acids among the human (NP_443091.1), mouse (NP_808483.2), zebra fish (XP_688354.3), 
fruit fly (NP_572246.1), nematode (NP_001023610.1) and budding yeast (NP_009533.1) 
proteins were mapped as in Figure 2. Membrane topology prediction of the RFT1 protein was 
performed like for the DPAGT1 enzyme (Fig. 4). A potential N-glycosylation site at position 
p.N227 is shown schematically. 
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ALG, asparagine-linked glycosylation; CDG, congenital disorders of glycosylation; ER, 
endoplasmic reticulum; IEF, isoelectric focusing; OST, oligosaccharyltransferase; MPI, 
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Table 1. Gene defects leading to deficient assembly of dolichol-linked oligosaccharides 
Gene OMIM a   Enzyme Disorder b Disorder c OMIM a Mutations Patients 
PMM2 601785 Phosphomannomutase 2 CDG-Ia PMM2-CDG 212065  103 > 800 
MPI 154550 Mannose phosphate isomerase CDG-Ib MPI-CDG 602579  18 >25 
DPAGT1 191350 GlcNAc-1-P transferase CDG-Ij DPAGT1-CDG 608093  3 3 
ALG1 605907 Mannosyltransferase 1 CDG-Ik ALG1-CDG 608540  4 7 
ALG2 607905 Mannosyltransferase 2 CDG-Ii ALG2-CDG 607906  2 1 
ALG3 608750 Mannosyltransferase 6 CDG-Id ALG3-CDG 601110  9 11 
ALG9 606941 Mannosyltransferase 7-9 CDG-Il ALG9-CDG 608776  2 3 
ALG12 607144 Mannosyltransferase 8 CDG-Ig ALG12-CDG 607143  11 8 
ALG6 604566 Glucosyltransferase 1 CDG-Ic ALG6-CDG 603147  20 >36 
ALG8 608103 Glucosyltransferase 2 CDG-Ih ALG8-CDG 608104  12 9 
DOLK 610746 Dolichol kinase CDG-Im DOLK-CDG 610768  2 4 
DPM1 603503 Dolichol-P mannosyltransferase 1 CDG-Ie DPM1-CDG 608799  6 8 
DPM3 605951 Dolichol-P mannosyltransferase 3 CDG-Io DPM3-CDG 612937 1 1 
MPDU1 604041 Man-P-dolichol utilization defect 1 CDG-If MPDU1-CDG 609180  5 5 
RFT1  611908 RFT1 homolog (S. cerevisiae) CDG-In RFT1-CDG 612015  5 6 
  
a http://www.ncbi.nlm.nih.gov/sites/entrez?db=OMIM 
b According to the recommended nomenclature of 1999 (Aebi, et al., 1999) 
c According to the recommended nomenclature of 2008 (Jaeken, et al., 2008) 
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Supporting table S1: Mutations in the PMM2 gene (NM_000303.2). Nucleotide numbering 
reflects cDNA numbering with +1 corresponding to the A of the ATG translation initiation 
codon in the reference sequence. 
Exon/Intron Base change Amino acid change  Reference 
Exon 1 c.1A>G p.M1V (Perez-Duenas, et al., 2009) 
Exon 1 c.24delC Frameshift (Matthijs, et al., 2000) 
Exon 1 c.26G>A p.C9Y (Matthijs, et al., 2000) 
Exon 1 c.32TC>GT p.F11C (Matthijs, et al., 2000) 
Exon 1 c.43G>C p.G15R (Schollen, et al., 2002) 
Exon 1 c.44G>C p.G15A This study a 
Exon 1 c.44G>A p.G15E (Callewaert, et al., 2003) 
Exon 1 c.53C>G p.T18S (Le Bizec, et al., 2005) 
Exon 1 c.58C>T p.P20S (Le Bizec, et al., 2005) 
Exon 1 c.61C>G p.R21G This study a 
Exon 1 c.64C>T p.Q22X This study a 
Intron 1 c.66+1G>T Splice variant (Le Bizec, et al., 2005) 
Intron 1 c.67-1G>A Abnormal splicing of exon 2 (Westphal, et al., 2001a) 
Exon 2 c.95TA>GC p.L32R (Matthijs, et al., 2000) 
Exon 2 c.104T>A p.L35X (Truin, et al., 2008) 
Exon 2 c.111G>T p.Q37H (SNP) (Le Bizec, et al., 2005) 
Exon 2 c.124G>A p.G42R This study a 
Exon 2 c.131T>C p.V44A (Matthijs, et al., 1999) 
2	
	
Exon 2 c.140C>A p.S47X (Le Bizec, et al., 2005) 
Exon 2 c.152A>G p.K51R (Vermeer, et al., 2007) 
Exon 2 c.161-162insG Frameshift (Wurm, et al., 2007) 
Exon 2 c.169G>C p.G57R This study a 
Intron 2 c.179-25A>G Skipping exon 3 (Vuillaumier-Barrot, et al., 2006) 
Exon 3 c.191A>G p.Y64C (Briones, et al., 2002) 
Exon 3 c.193G>T p.D65Y (Matthijs, et al., 1999) 
Exon 3 c.199G>A p.V67M (Matthijs, et al., 2000) 
Exon 3 c.200T>G p.V67G (Coman, et al., 2005) 
Exon 3 c.205C>T p.P69S (Matthijs, et al., 1999) 
Exon 3 c.227A>G p.Y76C (Matthijs, et al., 2000) 
Exon 3 c.255G>A p.Q85Q (splice variant) (Le Bizec, et al., 2005) 
Intron 3 c.255+1G>A Splice variant (Le Bizec, et al., 2005) 
Intron 3 c.255+2T>C Splice variant (Matthijs, et al., 1999) 
Intron 3 c.256-1G>C Skipping exons 3 and 4 (Vega, et al., 2009) 
Exon 4 c.278A>C p.E93A (Briones, et al., 2002) 
Exon 4 c.303C>G p.N101K (Matthijs, et al., 1999) 
Exon 4 c.308G>T p.C103F (Matthijs, et al., 2000) 
Exon 4 c.310C>G p.L104V (Westphal, et al., 2001a) 
Exon 4 c.317A>G p.Y106C (Matthijs, et al., 1997) 
Exon 4 c.323C>T p.A108V (Matthijs, et al., 1997) 
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Exon 4 c.324delG Frameshift (Matthijs, et al., 1999) 
Exon 4  c.338C>T p.P113L (Matthijs, et al., 1997) 
Exon 5 c.349G>C p.G117R (Matthijs, et al., 2000) 
Exon 5 c.357C>A p.F119L (Matthijs, et al., 1997) 
Exon 5 c.359T>C p.I120T (Matthijs, et al., 2000) 
Exon 5 c.367C>T p.R123X (Matthijs, et al., 2000) 
Exon 5 c.368G>A p.R123Q (Matthijs, et al., 1999) 
Exon 5 c.385G>A p.V129M (Matthijs, et al., 1997) 
Exon 5 c.389delC Frameshift (Matthijs, et al., 1999) 
Exon 5 c.391C>G p.P131A (Matthijs, et al., 1997) 
Exon 5 c.394A>T p.I132F (Le Bizec, et al., 2005) 
Exon 5 c.395T>C p.I132T (Matthijs, et al., 1999) 
Exon 5 c.395T>A p.I132N (Matthijs, et al., 2000) 
Exon 5 c.398delG Frameshift (Matthijs, et al., 2000) 
Exon 5 c.415G>A p.E139K (Matthijs, et al., 2000) 
Exon 5 c.421C>T p.R141C (Le Bizec, et al., 2005) 
Exon 5 c.422G>A p.R141H (Matthijs, et al., 1997) 
Exon 5 c.430T>C p.F144L (Mizugishi, et al., 1999) 
Exon 5 c.442G>A p.D148N (Matthijs, et al., 2000) 
Exon 6 c.451-454delGAAA Frameshift (Schollen, et al., 2002) 
Exon 6 c.452A>G p.E151G (Matthijs, et al., 1999) 
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Exon 6 c.458T>C p.I153T (Matthijs, et al., 2000) 
Exon 6 c.470T>C p.F157S (Matthijs, et al., 1999) 
Exon 6 c.484C>T p.R162W (Matthijs, et al., 1997) 
Exon 6 c.514T>G p.F172V (Matthijs, et al., 2000) 
Exon 6 c.523G>C p.G175R (Matthijs, et al., 1999) 
Exon 7 c.527G>T p.G176V (Le Bizec, et al., 2005) 
Exon 7 c.531G>C p.Q177H (Le Bizec, et al., 2005) 
Exon 7 c.548T>C p.F183S (Matthijs, et al., 2000) 
Exon 7 c.554A>G p.D185G (Matthijs, et al., 2000) 
Exon 7 c.563A>G p.D188G (Matthijs, et al., 1999) 
Exon 7 
c.565-571delAGAGAT 
insGTGGATTTCC 
Frameshift (Tayebi, et al., 2002) 
Exon 7 c.574T>G p.C192G (Matthijs, et al., 2000) 
Exon 7 c.580C>T p.R194X (Ono, et al., 2003) 
Exon 7 c.584A>G p.H195R (Matthijs, et al., 1999) 
Exon 7 c.590A>C p.E197A (SNP) (Matthijs, et al., 2000) 
Exon 7 c.617T>C p.F206S (Matthijs, et al., 2000) 
Exon 7 c.618C>A p.F206L (Thong, et al., 2009) 
Exon 7 c.620T>C p.F207S (Briones, et al., 2002) 
Exon 7 c.623G>C p.G208A (Matthijs, et al., 1999) 
Intron 7 c.640-15479C>T 
In frame insertion of 41 amino 
acids between exons 7 and 8 
(Schollen, et al., 2007) 
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Intron 7 c.640-23A>G Loss of exon 8 (Vuillaumier-Barrot, et al., 2006) 
Intron 7 c.640-9T>G Splice variant (Vega, et al., 2009) 
Exon 8 c.640G>A p.G214S (Le Bizec, et al., 2005) 
Exon 8 c.647A>T p.N216I (Matthijs, et al., 1997) 
Exon 8 c.G647A>G p.N216S (Matthijs, et al., 2000) 
Exon 8 c.651C>A p.D217E (Matthijs, et al., 2000) 
Exon 8 c.653A>T p.H218L (Matthijs, et al., 1999) 
Exon 8 c.667G>A p.D223N This study a 
Exon 8 c.669C>G p.D223E (Matthijs, et al., 2000) 
Exon 8 c.677C>G p.T226S (Matthijs, et al., 2000) 
Exon 8 c.682G>T p.G228C (Matthijs, et al., 1999) 
Exon 8 c.682G>C p.G228R (Matthijs, et al., 2000) 
Exon 8 c.686A>C p.Y229S (Matthijs, et al., 1999) 
Exon 8 c.691G>A p.V231M (Matthijs, et al., 1997) 
Exon 8 c.697G>A p.A233T (SNP) (Matthijs, et al., 1999) 
Exon 8 c.710C>G p.T237R (Matthijs, et al., 1999) 
Exon 8 c.710C>T p.T237M (Matthijs, et al., 1997) 
Exon 8 c.712C>G p.R238G (Matthijs, et al., 2000) 
Exon 8 c.713G>C p.R238P (Matthijs, et al., 1999) 
Exon 8 c.715A>T p.R239W (Grunewald, et al., 2001) 
Exon 8 c.722G>C p.C241S (Matthijs, et al., 1999) 
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Exon 8 c.728T>C p.L243P This study a 
Exon 8 
Alu retrotransposition 
mediated deletion  
Loss of exon 8  (Schollen, et al., 2007) 
  
a  Mutations identified through the Euroglycanet network (Matthijs, 2005)  
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Supporting table S2: Mutations in the MPI gene (NM_002435.1). Nucleotide numbering 
reflects cDNA numbering with +1 corresponding to the A of the ATG translation initiation 
codon in the reference sequence. 
Exon/Intron Base change Amino acid change  Reference 
Exon 3 c.152T>C p.M51T (Schollen, et al., 2000) 
Exon 3 c.166-167insC Frameshift (Schollen, et al., 2000) 
Exon 3 c.282delG Frameshift (Vuillaumier-Barrot, 2005) 
Exon 3 c.305C>T p.S102L (Jaeken, et al., 1998) 
Exon 4 c.386A>G p.Y129C (Schollen, et al., 2002) 
Exon 4 c.391G>A p.D131N (Schollen, et al., 2000) 
Exon 4 c.413T>C p.M138T (Jaeken, et al., 1998) 
Exon 4 c.419T>C p.I140T (Westphal, et al., 2001b) 
Exon 4 c.455G>A p.R152Q (Schollen, et al., 2000) 
Exon 4 c.466G>A p.E156K (Vuillaumier-Barrot, 2005) 
Intron 4 c.488-1G>C Splice variant  (Schollen, et al., 2000) 
Exon 5 c.656G>A p.R219Q (Niehues, et al., 1998) 
Exon 6 c.748G>A p.G250S (Schollen, et al., 2000) 
Exon 6 c.764A>G p.Y255C (de Lonlay, et al., 1999) 
Exon 7 c.884G>A p.R295H (Vuillaumier-Barrot, et al., 2002) 
Exon 8 c.1193T>C p.I398T (de Lonlay, et al., 1999) 
Exon 8 c.1252C>T p.R418C This study a 
Exon 8 c.1253G>A p.R418H (Babovic-Vuksanovic, et al., 1999) 
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a  Mutations identified through Euroglycanet network (Matthijs, 2005)  
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Supporting table S3: Mutations in the DPAGT1 gene (NM_001382.3). Nucleotide 
numbering reflects cDNA numbering with +1 corresponding to the A of the ATG translation 
initiation codon in the reference sequence. 
Exon/Intron Base change Amino acid change  Reference 
Intron 1 c.162-8G>A Splice variant  (Vuillaumier-Barrot, 2005) 
Exon 4 c.509A>G p.Y170C (Wu, et al., 2003) 
Exon 6 c.889A>T p.I297F (Vuillaumier-Barrot, 2005) 
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Supporting table S4: Mutations in the ALG1 gene (NM_019109.4). Nucleotide numbering 
reflects cDNA numbering with +1 corresponding to the A of the ATG translation initiation 
codon in the reference sequence. 
Exon/Intron Base change Amino acid change  Reference 
Exon 4 c.450C>G p.S150R (Grubenmann, et al., 2004) 
Exon 7 c.773C>T p.S258L (Schwarz, et al., 2004) 
Exon 10 c.1025A>C p.Q342P (Kranz, et al., 2004) 
Exon 13 c.1287T>A p.D429E (SNP) (Grubenmann, et al., 2004) 
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Supporting table S5: Mutations in the ALG2 gene (NM_033087.3). Nucleotide numbering 
reflects cDNA numbering with +1 corresponding to the A of the ATG translation initiation 
codon in the reference sequence. 
Exon/Intron Base change Amino acid change  Reference 
Exon 2 c.393G>T p.K131N (Thiel, et al., 2003) 
Exon 2 c.1040delG Frameshift  (Thiel, et al., 2003) 
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Supporting table S6: Mutations in the ALG3 gene (NM_005787.5). Nucleotide numbering 
reflects cDNA numbering with +1 corresponding to the A of the ATG translation initiation 
codon in the reference sequence. 
Exon/Intron Base change Amino acid change  Reference 
Exon 1 c.116C>T p.P39L (Rimella-Le-Huu, et al., 2008) 
Exon 1 c.165C>T Splice variant (Denecke, et al., 2004) 
Exon 2 c.211T>C p.W71R (Schollen, et al., 2002) 
Exon 2 c.262T>C p.Y88H This study a 
Exon 3 c.353G>A p.G118D (Körner, et al., 1998) 
Exon 4 c.470T>A p.M157K (Kranz, et al., 2007c) 
Exon 4 c.512G>A p.R171Q (Sun, et al., 2005) 
Exon 6 c.796C>T p.R266C (Schollen, et al., 2005) 
Exon 8 c.1060C>T p.R354C This study a 
  
a  Mutations identified through Euroglycanet network (Matthijs, 2005) 
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Supporting table S7: Mutations in the ALG9 gene (NM_001077690.1). Nucleotide 
numbering reflects cDNA numbering with +1 corresponding to the A of the ATG translation 
initiation codon in the reference sequence. 
Exon/Intron Base change Amino acid change  Reference 
Exon 8 c.860A>G p.Y287C (Weinstein, et al., 2005) 
Exon 13 c.1567G>A p.E523K (Frank, et al., 2004) 
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Supporting table S8: Mutations in the ALG12 gene (NM_024105.3). Nucleotide numbering 
reflects cDNA numbering with +1 corresponding to the A of the ATG translation initiation 
codon in the reference sequence. 
Exon/Intron Base change Amino acid change  Reference 
Exon 2 c.29delG Frameshift (Eklund, et al., 2005) 
Exon 3 c.200C>T p.T67M (Grubenmann, et al., 2002) 
Exon 3 c.241G>A p.A81T (Di Rocco, et al., 2005) 
Exon 4 c.301G>A p.G101R (Kranz, et al., 2007a) 
Exon 4 c.424T>G p.F142V (Chantret, et al., 2002) 
Exon 4 c.437G>A p.R146Q (Grubenmann, et al., 2002) 
Exon 5 c.473T>C p.L158P (Thiel, et al., 2002) 
Exon 6 c.688T>G p.Y230D (Eklund, et al., 2005) 
Exon 7 c.824G>A p.S275N (Eklund, et al., 2005) 
Exon 7 c.931C>T p.R311C (Eklund, et al., 2005) 
Exon 10 c.1242C>G p.Y414X (Thiel, et al., 2002) 
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Supporting table S9: Mutations in the ALG6 gene (NM_013339.3). Nucleotide numbering 
reflects cDNA numbering with +1 corresponding to the A of the ATG translation initiation 
codon in the reference sequence. 
Exon/Intron Base change Amino acid change  Reference 
Exon 1 c.53G>A p.R18Q This study a 
Exon 3 c.171T>A p.Y57X (Vuillaumier-Barrot, 2005) 
Intron 3 c.257+2-3insT Skipping Exon 3 (Newell, et al., 2003) 
Intron 3 c.257+5G>A Skipping exon 3 (Imbach, et al., 2000a) 
Exon 4 c.338G>A p.R113H (Eklund, et al., 2006) 
Intron 4 c.347-13G>C Splice variant (Vuillaumier-Barrot, 2005) 
Exon 5 c.391T>C p.Y131H (SNP) (Westphal, et al., 2000a) 
Exon 7 c.509G>T p.S170I (de Lonlay, et al., 2001) 
Exon 7 c.680G>A p.G227E (Schollen, et al., 2002) 
Intron 7 c.680+2T>G 
Skipping exons 7 – 12 and parts 
of exon 13 
(Sun, et al., 2005) 
Exon 9 c.895-897delATA p.I299del (Westphal, et al., 2000b) 
Exon 9 c.896-898delTAA p.I299del (Hanefeld, et al., 2000) 
Exon 9 c.897-899delAAT p.I299del (Sun, et al., 2005) 
Exon 10 c.908-910delGTT p.C303del This study a 
Exon 10 c.911T>C p.F304S (SNP) (Vuillaumier-Barrot, et al., 2001) 
Exon 10 c.924C>A p.S308R (Westphal, et al., 2000a) 
Exon 11 c.998C>T p.A333V (Imbach, et al., 1999) 
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Exon 14 c.1330-1332delCTT p.L444del (de Lonlay, et al., 2001) 
Exon 14 c.1432T>C p.S478P (Imbach, et al., 2000a) 
- Del(1)(p31.2p32.3) No protein (Eklund, et al., 2006) 
  
a  Mutations identified through Euroglycanet network (Matthijs, 2005)  
17	
	
Supporting table S10: Mutations in the ALG8 gene (NM_024079.4). Nucleotide numbering 
reflects cDNA numbering with +1 corresponding to the A of the ATG translation initiation 
codon in the reference sequence. 
Exon/Intron Base change Amino acid change  Reference 
Intron 1 c.96-2A>G Splice variant  (Schollen, et al., 2004) 
Exon 2 c.139A>C p.T47P (Schollen, et al., 2004) 
Exon 3 c.206C>T p.P69L This study a 
Exon 4 c.396-397insA Frameshift (Chantret, et al., 2003) 
Exon 4 c.413delC Frameshift (Chantret, et al., 2003) 
Exon 6 c.665A>G p.N222S (SNP) (Schollen, et al., 2004) 
Intron 6 c.672+4A>G Skipping exon 6 (Schollen, et al., 2004) 
Intron 7 c.778-3C>A Splice variant This study a 
Exon 8 c.824G>A p.G275D (Schollen, et al., 2004) 
Exon 8 c.845C>T p.A282V (Stölting, et al., 2009) 
Exon 10 c.1090C>T p.R364X (Vesela, et al., 2009) 
Exon 13 c.1434delC Frameshift (Stölting, et al., 2009) 
  
a  Mutations identified through Euroglycanet network (Matthijs, 2005) 
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Supporting table S11: Mutations in the DOLK gene (NM_014908.3). Nucleotide numbering 
reflects cDNA numbering with +1 corresponding to the A of the ATG translation initiation 
codon in the reference sequence. 
Exon/Intron Base change Amino acid change  Reference 
Exon 1 c.295T>A p.C99S (Kranz, et al., 2007b) 
Exon 1 c.1322A>C p.Y441S (Kranz, et al., 2007b) 
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Supporting table S12: Mutations in the DPM1 gene (NM_003859.1). Nucleotide numbering 
reflects cDNA numbering with +1 corresponding to the A of the ATG translation initiation 
codon in the reference sequence. 
Exon/Intron Base change Amino acid change  Reference 
Exon 3 c.274C>G p.R92G (Imbach, et al., 2000b) 
Exon 4 
c.331-343del 
GGAAACTACATCA 
Frameshift (Kim, et al., 2000) 
Intron 4 c.373-5T>A Skipping exon 5 (Dancourt, et al., 2006) 
Exon 7 c.506A>G p.N169S (Vuillaumier-Barrot, 2005) 
Exon 8 c.628delC Frameshift (Imbach, et al., 2000b) 
Exon 9 c.742T>C p.S248P (Garcia-Silva, et al., 2004) 
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Supporting table S13: Mutations in the DPM3 gene (NM_153741.1). Nucleotide numbering 
reflects cDNA numbering with +1 corresponding to the A of the ATG translation initiation 
codon in the reference sequence. 
Exon/Intron Base change Amino acid change  Reference 
Exon 1 c.254T>C p.L85S (Lefeber, et al., 2009) 
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Supporting table S14: Mutations in the MPDU1 gene (NM_004870.3). Nucleotide 
numbering reflects cDNA numbering with +1 corresponding to the A of the ATG translation 
initiation codon in the reference sequence.  
Exon/Intron Base change Amino acid change  Reference 
Exon 1 c.2T>C p.M1T (Schenk, et al., 2001) 
Exon 3 c.218G>A p.G73E (Schenk, et al., 2001) 
Exon 3 c.221T>C p.L74S (Kranz, et al., 2001) 
Exon 4 c.356T>C p.L119P (Schenk, et al., 2001) 
Exon 6 c.511delC Frameshift (Schenk, et al., 2001) 
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Supporting table S15: Mutations in the RFT1 gene (NM_052859.3). Nucleotide numbering 
reflects cDNA numbering with +1 corresponding to the A of the ATG translation initiation 
codon in the reference sequence. 
Exon/Intron Base change Amino acid change  Reference 
Exon 3 c.199C>T p.R67C (Haeuptle, et al., 2008) 
Exon 4 c.454A>G p.K152E (Vleugels, et al., 2009) 
Exon 9 c.887T>A p.I296K This study a 
Exon 9 c.887T>G p.I296R This study a 
Exon 9 c.892G>A p.E298K (Vleugels, et al., 2009) 
  
a  Mutations identified through Euroglycanet network (Matthijs, 2005) 
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Supporting	Methods:		
Mutations	presented	for	the	first	time	in	this	study	were	detected	by	sequencing	cDNA	
and	genomic	DNA	isolated	from	fibroblasts.	Total	RNA	and	genomic	DNA	were	prepared	
from	 approximately	 2	 x	 107	 fibroblasts	 using	 the	 TRIzol	 LS	 reagent	 (Invitrogen)	
according	 to	 the	 manufacturer’s	 instructions.	 mRNA	 was	 reverse	 transcribed	 using	
Omniscript	 reverse	 transcriptase	 (QUIAGEN).	 The	 resulting	 cDNA	 samples	 were	
amplified	 by	 PCR	 utilizing	 forward	 and	 reverse	 primers	 flanking	 the	 protein	 coding	
regions.	 After	 removal	 of	 unincorporated	 nucleotides	 using	 QUIAquick	 columns	
(QUIAGEN),	 the	 purified	 PCR	 products	 were	 directly	 sequenced.	 Identified	 mutations	
were	confirmed	at	 the	genomic	 level	by	sequencing	 the	corresponding	exons.	Putative	
single	 nucleotide	 polymorphisms	 were	 excluded	 by	 analyzing	 at	 least	 230	 control	
alleles.	 	
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